Novo Nordisk Governance Shakeup Sparks Investor Concerns
Published on 11/15/2025 at 16:27 | Redaktion boerse-global.de
A dramatic boardroom overhaul at pharmaceutical giant Novo Nordisk has cemented the controlling foundation’s authority, triggering apprehension among minority shareholders about corporate governance standards. During an extraordinary general meeting, investors overwhelmingly approved a radical restructuring of the supervisory board that consolidates power with the Novo Nordisk Foundation.
Lars Rebien Sørensen, previously chairman of the foundation, now assumes the dual role of supervisory board chairman for the pharmaceutical company—an unprecedented concentration of influence in the corporation’s history. This development follows the unexpected October departures of former board chair Helge Lund and several independent members, who cited irreconcilable differences with the foundation regarding governance practices and strategic direction.
With Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
